Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vital Therapies Announces Recent and Upcoming Scientific Presentations and Participation in Upcoming Investor Conference
SAN DIEGO , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today provides an update on recent and upcoming scientific presentations.
View HTML
Toggle Summary Vital Therapies Appoints Former Receptos President and CEO Faheem Hasnain as Chairman of the Board of Directors
SAN DIEGO , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced the appointment of Faheem Hasnain as Chairman of the Board of Directors,
View HTML
Toggle Summary Vital Therapies Announces Second Quarter 2017 Financial Results
SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the second quarter ended June 30, 2017.
View HTML
Toggle Summary Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast
SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its second quarter 2017 financial results after the market closes on Thursday,
View HTML
Toggle Summary Vital Therapies Announces Characteristics of Early Subjects in VTL-308 Pivotal Study of ELAD System in Severe Alcoholic Hepatitis
SAN DIEGO, June 05, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today released data describing the baseline characteristics of the 67 subjects enrolled as
View HTML
Toggle Summary Vital Therapies Announces First Quarter 2017 Financial Results
SAN DIEGO, May 09, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the first quarter ended March 31, 2017.
View HTML
Toggle Summary Vital Therapies Announces Upcoming First Quarter Financial Results Conference Call With Webcast
SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its first quarter 2017 financial results after the market closes on Tuesday, May
View HTML
Toggle Summary Vital Therapies Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock in Public Offering
SAN DIEGO, March 29, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that in connection with its previously disclosed underwritten public
View HTML
Toggle Summary Vital Therapies Announces Pricing of Public Offering of Common Stock
SAN DIEGO, March 22, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD ® , a cell-based therapy targeting the treatment of acute forms of liver failure, today announced the pricing of an underwritten public offering of 8,750,000 newly
View HTML
Toggle Summary Vital Therapies Announces Proposed Public Offering of Common Stock
SAN DIEGO, March 21, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver failure, today announced that it intends to offer to sell shares of its common stock in an underwritten
View HTML